Palovarotene: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Palovarotene. Educational only — not medical advice.
Labeled uses
SOHONOS is indicated for the reduction in volume of new heterotopic ossification in adults and pediatric patients aged 8 years and older for females and 10 years and older for males with fibrodysplasia ossificans progressiva (FOP).
Source: FDA labeling via NIH DailyMed (set 67dce406…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.